| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
As a chemical intermediate, (1R,2R)-Cyclohexane-1,2-diamine does not have a specific biological target. Its pharmaceutical relevance stems from its use as a building block for synthesizing active pharmaceutical ingredients (APIs), most notably oxaliplatin, where it coordinates to the platinum center as a chiral ligand. The resulting platinum complex targets DNA in cancer cells, forming cross-links that inhibit DNA replication and transcription, leading to cell death. The compound itself is not pharmacologically active but serves as a crucial chiral auxiliary in asymmetric synthesis.
|
|---|---|
| ln Vitro |
Can be employed as chiral ligand building blocks.
(1R,2R)-Cyclohexane-1,2-diamine is a chemical intermediate and does not possess intrinsic in vitro biological activity. Its value in research lies in its utility for synthesizing biologically active compounds, particularly chiral pharmaceuticals and asymmetric catalysts. As a chiral diamine, it is used to prepare metal complexes for asymmetric catalysis, which are then employed in the synthesis of enantiomerically pure drug candidates. It may also be used in the synthesis of compounds that are subsequently tested for various biological activities. |
| ln Vivo |
This compound is not a pharmacologically active agent and does not have intrinsic in vivo activity. Its applications in vivo are indirect, as it is used to synthesize drug candidates such as oxaliplatin, which is then evaluated in animal models and clinical settings for anticancer efficacy. The compound itself is not administered to animals as a test compound.
|
| Enzyme Assay |
Cell-free enzyme/receptor binding assays are not directly applicable to (1R,2R)-Cyclohexane-1,2-diamine as it is not a biologically active compound. However, when used to synthesize metal complexes or drug candidates, these products may be evaluated in binding assays. Typical protocols involve incubating the test compound with purified target proteins in buffered solutions, with binding affinity measured by SPR, ITC, or fluorescence-based methods. The chiral nature of the compound makes it valuable for studying stereoselective interactions with chiral biological targets.
|
| Cell Assay |
Cell-based assays are not directly performed on (1R,2R)-Cyclohexane-1,2-diamine due to its lack of biological activity. However, drug candidates synthesized from this intermediate, such as oxaliplatin, are extensively studied in cellular systems. For anticancer agents, typical assays involve culturing cancer cell lines (e.g., HCT-116, A549, or MCF-7) in appropriate media, treating with varying concentrations of the test compound, and assessing cell viability (MTT), apoptosis (flow cytometry), and DNA damage (comet assay) over 24–72 hours.
|
| Animal Protocol |
In vivo animal studies are not conducted with (1R,2R)-Cyclohexane-1,2-diamine itself, as it is a chemical intermediate. However, oxaliplatin and other drug candidates derived from this intermediate are evaluated in animal models. Typical studies involve intravenous administration to tumor-bearing mice, with monitoring of tumor growth inhibition, survival, body weight, and hematological parameters. Pharmacokinetic parameters (Cmax, AUC, half-life) are determined from plasma samples. All studies follow institutional animal care guidelines.
|
| ADME/Pharmacokinetics |
(1R,2R)-Cyclohexane-1,2-diamine is a synthetic chemical intermediate and is not subject to pharmacokinetic evaluation as a drug. Its physicochemical properties include a molecular weight of 114.19 g/mol and a molecular formula of C6H14N2. As a chiral diamine, it is stored at 20°C and is stable for up to 2 years. The compound is used as an epoxy resin curing agent and as a chiral synthetic reagent.
|
| Toxicity/Toxicokinetics |
The toxicological profile of (1R,2R)-Cyclohexane-1,2-diamine as a pure chemical reagent has not been extensively characterized. As a diamine compound, it may cause skin and eye irritation upon contact. Standard laboratory safety precautions should be observed, including the use of personal protective equipment (gloves, goggles, lab coat) and adequate ventilation. Ingestion or inhalation should be avoided. Appropriate first-aid measures should be in place, and spills should be cleaned up promptly.
|
| Additional Infomation |
DNH is an amine.
(1R,2R)-Cyclohexane-1,2-diamine is not a drug but a valuable chiral building block in pharmaceutical synthesis. Its most notable application is as a key intermediate in the synthesis of oxaliplatin, a platinum-based anticancer drug used in the treatment of colorectal cancer. The chiral nature of the compound (the (1R,2R) enantiomer) is critical for the biological activity of oxaliplatin. It is also used as a chiral auxiliary and ligand in asymmetric catalysis for the synthesis of enantiomerically pure pharmaceuticals. The compound is available in high purity (≥96–98%) for research and manufacturing use. |
| Molecular Formula |
C6H14N2
|
|---|---|
| Molecular Weight |
114.19
|
| Exact Mass |
114.115
|
| CAS # |
20439-47-8
|
| Related CAS # |
(1S,2S)-Cyclohexane-1,2-diamine;21436-03-3
|
| PubChem CID |
43806
|
| Appearance |
Colorless to light yellow <41°C solid powder,>45°C liquid
|
| Density |
0.9±0.1 g/cm3
|
| Boiling Point |
193.6±0.0 °C at 760 mmHg
|
| Melting Point |
41-45 °C
|
| Flash Point |
76 ºC
|
| Vapour Pressure |
0.5±0.3 mmHg at 25°C
|
| Index of Refraction |
1.484
|
| LogP |
-0.12
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
8
|
| Complexity |
62.9
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
N([H])([H])[C@]1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])N([H])[H]
|
| InChi Key |
SSJXIUAHEKJCMH-PHDIDXHHSA-N
|
| InChi Code |
InChI=1S/C6H14N2/c7-5-3-1-2-4-6(5)8/h5-6H,1-4,7-8H2/t5-,6-/m1/s1
|
| Chemical Name |
(1R,2R)-cyclohexane-1,2-diamine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: (1). This product requires protection from light (avoid light exposure) during transportation and storage. (2). Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O: 100 mg/mL (875.73 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 8.7573 mL | 43.7867 mL | 87.5733 mL | |
| 5 mM | 1.7515 mL | 8.7573 mL | 17.5147 mL | |
| 10 mM | 0.8757 mL | 4.3787 mL | 8.7573 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
